Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab combinations in relapsed/refractory B-cell non-Hodgkin lymphoma
2023-505222-34-00Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of glofitamab, atezolizumab, polatuzumab vedotin and obinutuzumab in mature B-cell lymphoma and B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Roche. Primary endpoints: Best overall response rate and Dose-limiting toxicities. Started Apr 2018; status: completed.
02
Drugs
glofitamabatezolizumabpolatuzumab vedotinobinutuzumab
03
Conditions
mature B-cell lymphomaB-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2023-505222-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505222-34-00.